secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001854270-25-000088
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Bio Q2 2025 net loss $14.7M; completes dose finding for SENTI-202 AML trial, RP2D confirmed
--------------------------------------------------------------------------------

- Net loss of $14.7M ($0.56 per share); cash $21.6M as of June 30, 2025, down from $48.3M at Dec 31, 2024.
- Completed dose finding and confirmed RP2D for Phase 1 SENTI-202 trial in AML; now in dose expansion.
- Received FDA Orphan Drug Designation for SENTI-202 in AML.
- Received $1.0M from CIRM grant; added Bryan Baum to Board, Dr. James Trager to Scientific Advisory Board.
- Expect additional efficacy and durability data from SENTI-202 Phase 1 study in Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000185427025000088/0001854270-25-000088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000185427025000088/snti-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001854270-25-000088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer